Mvasi® (bevacizumab-awwb) – Updated indication and boxed warning removal

- On June 24, 2019, the FDA approved Amgen's Mvasi (bevacizumab-awwb), for recurrent glioblastoma in adults.
    - Previously, the indication was glioblastoma, as a single agent for adult patients with progressive disease following prior therapy.
    - The updated indication is the same as the reference product, Genentech's Avastin (bevacizumab).
- Mvasi and Avastin are also indicated for metastatic colorectal cancer; non-squamous non-small cell lung cancer; metastatic renal cell carcinoma; and persistent, recurrent, or metastatic carcinoma of the cervix.
- Avastin carries an additional indication for epithelial ovarian, fallopian tube, or primary peritoneal cancer.
- In addition, the *boxed warning* for gastrointestinal perforations, surgery and wound healing complications, and hemorrhage was removed from the Mvasi label.
    - The *boxed warning* was also removed from the Avastin drug label on June 20, 2019.